ZGNX - WeissLaw LLP Investigates Zogenix Inc.
NEW YORK, May 31, 2019 /PRNewswire/ -- WeissLaw LLP, a national class action and shareholders' rights law firm, announces an investigation of Zogenix, Inc. ("Zogenix" or the "Company) (NASDAQ: ZGNX).
The investigation focuses on possible breaches of fiduciary duty and violations of the Federal securities laws by the Zogenix Board of Directors for allegedly disseminating materially false and/or misleading information in connection with FINTEPLA, the Company's investigational anti-seizure therapy for patients with Dravet syndrome. Namely, that Zogenix failed to disclose that it submitted an incorrect dataset and omitted certain key information related to the long-term administration of an active substance in FINTEPLA in its New Drug Application with the FDA. Consequently, the Company received a Refusal to File letter from the FDA which will delay its application and strengthen the position of its recently approved competitor, Epidiolex. Moreover, according to Seeking Alpha, this setback "should [] be viewed as a binary event with a 50/50 chance of complete failure."
If you own Zogenix shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
Visit our website
http://www.weisslawllp.com/zogenix-inc/
Or follow us on Twitter @MarketsAlert
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com.
SOURCE WeissLaw LLP